← Back to patent-cliff list
Atorvastatin Calcium Hydrate/Hyzetimibe
Tier C — Watch / tradeAtorvastatin Calcium Hydrate/Hyzetimibe
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：NPC1L1
Indications (approved)：Hypercholesterolaemia, Hyperlipidaemia, 家族性混合型高脂血症, Heterozygous familial hypercholesterolaemia
Regional status
US
-
EU
-
China
Phase III
2026-06-10
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Atorvastatin Calcium Hydrate/Hyzetimibe?
Approved indications include: Hypercholesterolaemia, Hyperlipidaemia, 家族性混合型高脂血症, Heterozygous familial hypercholesterolaemia.
When does the Atorvastatin Calcium Hydrate/Hyzetimibe patent expire?
No public expiry year is available for Atorvastatin Calcium Hydrate/Hyzetimibe yet; this page updates once verified.
How do I get a quote for Atorvastatin Calcium Hydrate/Hyzetimibe intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-11